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Abstract
Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical ne-
glected tropical disease. Specific immunity promotes acute phase survival. Nevertheless,
one-third of CD patients develop chronic chagasic cardiomyopathy (CCC) associated with
parasite persistence and immunological unbalance. Currently, the therapeutic management
of patients only mitigates CCC symptoms. Therefore, a vaccine arises as an alternative to
stimulate protective immunity and thereby prevent, delay progression and even reverse
CCC. We examined this hypothesis by vaccinating mice with replication-defective human
Type 5 recombinant adenoviruses (rAd) carrying sequences of amastigote surface protein-
2 (rAdASP2) and trans-sialidase (rAdTS) T. cruzi antigens. For prophylactic vaccination,
naïve C57BL/6 mice were immunized with rAdASP2+rAdTS (rAdVax) using a homologous
prime/boost protocol before challenge with the Colombian strain. For therapeutic vaccina-
tion, rAdVax administration was initiated at 120 days post-infection (dpi), when mice were
afflicted by CCC. Mice were analyzed for electrical abnormalities, immune response and
cardiac parasitism and tissue damage. Prophylactic immunization with rAdVax induced
antibodies and H-2Kb-restricted cytotoxic and interferon (IFN)γ-producing CD8+ T-cells, re-
duced acute heart parasitism and electrical abnormalities in the chronic phase. Therapeutic
vaccination increased survival and reduced electrical abnormalities after the prime (analysis
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at 160 dpi) and the boost (analysis at 180 and 230 dpi). Post-therapy mice exhibited less
heart injury and electrical abnormalities compared with pre-therapy mice. rAdVax therapeu-
tic vaccination preserved specific IFNγ-mediated immunity but reduced the response to
polyclonal stimuli (anti-CD3 plus anti-CD28), CD107a+ CD8+ T-cell frequency and plasma
nitric oxide (NO) levels. Moreover, therapeutic rAdVax reshaped immunity in the heart
tissue as reduced the number of perforin+ cells, preserved the number of IFNγ+ cells, in-
creased the expression of IFNγmRNA but reduced inducible NO synthase mRNA. Vac-
cine-based immunostimulation with rAd might offer a rational alternative for re-programming
the immune response to preserve and, moreover, recover tissue injury in Chagas’
heart disease.
Author Summary
The idea that Chagas disease (CD) has an important autoimmune involvement contribut-
ed to delay the development of therapies and vaccines. CD is a parasitic neglected disease
which afflicts millions of people mostly in Latin America. The cardiac form is the main
clinical manifestation of CD. Currently, patients with access to therapy receive medica-
ments that only mitigate symptoms. Because of the limited prospect of treatment, vaccine
reemerged as a strategy to prevent infection, interfere with CD progression and, moreover,
reverse heart abnormalities. Here we tested a recombinant adenovirus carrying sequences
of ASP2 and TS T. cruzi antigens (rAdVax) as prophylactic and therapeutic tool using a
model of chronic Chagas’ heart disease. We showed that prophylactic vaccination reduced
heart parasite load, inflammation and electrical abnormalities. The rAdVax therapeutic
vaccination also reduced heart injury and improved electrical function, preserved specific
IFNγ-mediated immunity but reduced response to polyclonal stimuli, CD107a+ CD8+ T-
cell frequency and plasma nitric oxide levels. Moreover, therapeutic rAdVax preserved the
number IFNγ+ cells, but decreased perforin+ cells in the heart tissue. Therefore, our results
support the hypothesis that vaccination can modify the immunological unbalance that
concurs to Chagas’ heart disease to improve prognosis.
Introduction
Chagas disease (CD) is a neglected tropical illness caused by the protozoan parasite
Trypanosoma cruzi, which is transmitted by blood-sucking triatomines. The disease afflicts
8 to 15 million people in Latin America; more than 40,000 new cases occur every year and the
rate of congenital transmission is greater than 14,000 cases per year. Furthermore, approxi-
mately 1 million immigrants to the USA and Europe have CD [1]. Despite the successful con-
trol of the main vector, an overview of the current challenges reveals the need for (i)
permanent vector surveillance and attention to domestic and peri-domestic reservoirs of the
parasite, (ii) new strategies to prevent or abrogate infection and (iii) new therapies for patients
with chronic forms of CD [2].
The most frequent and severe manifestation of CD is chronic chagasic cardiomyopathy
(CCC), which is associated with inflammation, myocytolysis and fibrosis and affects 20–40% of
infected individuals at 10–30 years after infection [1]. Innate and adaptive immunity play piv-
otal roles in parasite growth control during the acute phase of infection, allowing the establish-
ment of chronic phase [3]. However, in patients with Chagas’ heart disease the natural
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immune response is mostly inadequate as parasite persistence and parasite-induced deregu-
lated immune response are consensual explanations for CCC pathogenesis [4, 5]. Several stud-
ies have proposed veterinary vaccine as tools to prevent infection, particularly to decrease
parasitemia in hosts and reservoirs, such as dogs, to control the domestic and peri-domestic
cycle [6]. Furthermore, human vaccines would generate a positive return on investment, be-
cause such vaccines would prevent the onset of CCC and provide both cost savings and health
benefits [7]. In chronic T. cruzi infections, vaccination should be considered as a therapeutic
strategy to redirect immunity to a protective status to delay disease progression and reverse
heart alterations in chronic patients.
Many attempts to generate a prophylactic vaccine for CD have been conducted in the last
three decades, including use of the attenuated parasite, purified protein, recombinant protein
and DNA and, more recently, replication-deficient bacteria and recombinant viral vectors to
reduce acute parasitism and heart inflammation [8–11] and chronic myocarditis [12].
The amastigote surface protein-2 (ASP2), a protein with unknown function [13] and trans-
sialidase (TS), a trypomastigote-restricted enzyme that catalyzes the transfer of sialic acid from
host glycoproteins to acceptor molecules on the parasite membrane [14], are two of the most
promising candidates for vaccine development. Researchers have attempted to produce an
immunotherapeutic vaccine; however, these preparations were unable to control disease pro-
gression [10]. Furthermore, no vaccines that can reverse chronic Chagas’ heart disease
are available.
Vaccines using replication-deficient human recombinant Type 5 adenoviruses (AdHu5)
carrying sequences of the ASP2 (rAdASP2) and TS (rAdTS) proteins of the Y T. cruzi Type II
strain [15] elicited Th1-biased immunity with a substantial CD8+ T-cell-mediated long-term
protective immune response against challenge with the Y strain [16]. Furthermore, heterolo-
gous priming with plasmid DNA and boosting with rAdASP2 and rAdTS protected mice from
challenges with the CL and Colombian T. cruzi strains, thereby demonstrating cross protective
immunity [17]. Based on the results of previous studies, we tested the therapeutic properties of
combined rAdASP2+rAdTS (rAdVax) in a homologous prime-boost protocol to skew the im-
mune response to prevent, hamper progression and potentially reverse chronic Chagas’ heart
disease. Therefore, we challenged the idea that unappropriated immune response contributes
to cardiac abnormalities and once it has been reshaped heart damage progression may be de-
layed and, even, reversed.
Results
Prophylactic homologous prime-boost rAdVax administration reduces
parasite burden and protects from electrical abnormalities in chronic
experimental Chagas’ heart disease
Initially, we determined the ability of rAdVax to induce antibodies and specific CD8+ T-cells,
which are considered protective in T. cruzi infection [16, 17]. To this end, C57BL/6 mice were
vaccinated twice with rAdVax or rAdCtrl as described in the Materials and Methods section.
Three to four weeks after boosting, the sera were collected and analyzed using ELISA and the
CD8+ T-cell response was analyzed by in vivo cytotoxic assay and ELISpot for IFNγ detection
(S1A Fig.). Specific total antibodies (IgM+IgG) against recombinant ASP2 and TS proteins
were detected in rAdVax-immunized mice, whereas saline-injected or rAdCtrl-immunized
mice presented negligible reactivity to these proteins (S1B Fig.). Protection against T. cruzi de-
pends on CD8+ T-cell effector activities [4]. Significantly, high frequency of H-2kb-restricted
anti-VNHRFTLV CTL CD8+ T-cells were detected in the spleen of rAdVax vaccinated mice
but not in saline-injected or in rAdCtrl-immunized mice (S1C and S1D Fig.). Moreover,
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immunization with rAdVax induced a significant increase in the number of ASP2-specific
IFNγ-producing CD8+ T-cells, which are of pivotal importance in T. cruzi growth control [3].
In contrast, specific IFNγ-producing CD8+ T-cells were absent in saline-injected mice and the
number of these cells was reduced in rAdCtrl-immunized mice (S1E Fig.). Therefore, vaccina-
tion with rAdVax in a homologous prime-boost protocol stimulated anti-T. cruzi IgM+IgG an-
tibodies and parasite-specific CTL and IFNγ-producing CD8+ T-cells, corroborating our
previous data [16, 17].
Initially, we tested whether prophylactic rAdVax administration could reduce heart parasit-
ism and tissue damage in a model of acute phase of infection [17]. rAdVAx reduced the acute
heart parasitism and cardiomyocyte damage induced by the CL-Brener T. cruzi Type VI strain
(S2 Fig.). Next, we examined whether a homologous prime-boost vaccination with rAdVax
could prevent T. cruzi-induced CCC. When C57BL/6 mice are infected with 100 blood trypo-
mastigote (bt) forms of the Colombian strain, parasitemia peak occurs at 42–45 dpi, parasite-
mia control occurred from 60–70 dpi and chronic phase is established after 90 dpi, when none
or rare blood trypomastigotes are detected [5]. Importantly, in this model of T. cruzi infection
parasitemia and heart parasitism are directly associated and 70–85% of infected mice survived
and developed a chronic disease with electrical abnormalities [5, 18]. Therefore, vaccinated
C57BL/6 mice were challenged with 100 bt forms of the Colombian strain and tested for heart
tissue parasitism and electrical alterations in the acute and chronic infection (Fig. 1A). The
rAdVax vaccination did not alter parasitemia curve or the number of circulating parasites
at the peak of parasitemia at 42 dpi (34.7 ± 17 × 103 trypomastigotes/mL in rAdCtrl vs.
30.2 ± 15.7 × 103 trypomastigotes/mL in rAdVax; P> 0.05). Although the prophylactic admin-
istration of rAdVax did not affect T. cruzi-induced splenomegaly (Fig. 1B), the number of para-
site nests in the heart tissue was significantly reduced during the acute phase (Fig. 1C). rAdVax
did not alter the numbers of CD4+ cells and F4/80+ macrophages, but reduced the number of
CD8+ cells, infiltrating the cardiac tissue, at 50 dpi (S3 Fig.). Further, in rAdVax-vaccinated
mice no significant alterations in myocarditis were detected at 150 dpi (2206 ± 719 inflamma-
tory cell/100 microscopic fields in rAdCtrl vs. 1989 ± 934 inflammatory cell/100 microscopic
fields in rAdVax; P> 0.05). Electrical abnormalities, including low heart rate, arrhythmia
(ART) and first- and second-degree atrioventricular block (AVB1 and AVB2), are important
features of the chronic cardiomyopathy induced by infection with the Colombian T. cruzi
strain in C57BL/6 mice [5]. Notably, immunization with rAdVax remarkably decreased the fre-
quency of mice presenting ART, particularly sinus arrhythmia (sART) and AVB2 at 150 dpi
(Fig. 1D). Moreover, compared with rAdCtrl injection, rAdVax inoculation reduced the fre-
quency of mice afflicted with ART, AVB1 (100% in saline-injected, 100% in rAdCtrl-treated
and 20% in rAdVax), AVB2 and other electrical abnormalities (Fig. 1E). These observations
supported our hypothesis that rAdVax is a feasible tool to ameliorate the outcome of chronic
Chagas’ heart disease.
Homologous prime-boost rAdVax immunotherapy during chronic
infection delays progression and reverses chronic cardiomyopathy
induced by the Colombian strain
To test the hypothesis that a vaccine might delay progression and, even, reverse CCC, chroni-
cally infected mice (at 120 dpi) were subjected to the homologous prime-boost vaccination
with rAdVax (Fig. 2A). At 120 dpi, electrocardiogram (ECG) abnormalities, such as low heart
rate (Fig. 2B) and prolonged P wave, were evident (Fig. 2B and 2C). Indeed, an analysis of all T.
cruzi-infected mice showed that at 120 dpi (pre-therapy), 80% of the Colombian-infected
C57BL/6 mice were afflicted with electrical abnormalities (Fig. 2D). At 150 dpi, 100% of the
Therapeutic Vaccine for Chronic Chagas Disease
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Figure 1. Heart parasitism and electrical abnormalities are reduced in rAdVax-vaccinated mice
challenged with the Colombian strain. (A) Mice were primed-boosted (s.c.) with 2 × 108 plaque-forming
units (PFU) of rAdCtrl or a mixture of 108 PFU of each recombinant adenovirus vaccine construction
(rAdASP2+rAdTS; rAdVax) or the vehicle control saline at 6-week intervals. Four weeks after the last
immunization, the mice were challenged (i.p.) with 100 blood trypomastigotes (bt) of the Colombian T. cruzi
Type I strain and analyzed during the acute (50 dpi) and chronic (150 dpi) phases of infection. (B) Relative
spleen weight (mg of spleen/g of body). (C) Quantitative immunohistochemical staining data for T. cruzi
parasitism (nests/100 microscopic fields) in the heart tissue. (D) Representative electrocardiogram (ECG)
register segments of sex- and age-matched noninfected (NI) controls and mice injected with saline, rAdCtrl or
rAdVax, challenged with T. cruzi and analyzed at 150 dpi. (E) Summary of the group data from NI controls
and saline-injected, rAdCtrl- or rAdVax-immunized and T. cruzi-infected mice showing the frequency of mice
Therapeutic Vaccine for Chronic Chagas Disease
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not-treated or saline-injected Colombian-infected C57BL/6 mice presented ECG alterations
(as shown in Fig. 1E), corroborating previous data [18, 19]. At 160 dpi (40 days post-therapy
initiation), 100% of rAdCtrl-injected mice presented ART and 70% presented AVB2 in a man-
ner that 100% showed ECG abnormalities. In contrast, only 40% of rAdVax-immunized mice
presented electrical abnormalities, suggesting that immunotherapy with recombinant rAdVax
decreased the progression of CCC. Moreover, whereas 80% of T. cruzi-infected mice presented
ART and other ECG abnormalities before therapy (at 120 dpi), only 40% of rAdVax-vaccinated
mice presented ART and AVB2 at 230 dpi. Taken together, these data demonstrated that ho-
mologous prime-boost immunotherapy with rAdVax vaccine reversed the chronic electrical
conduction abnormalities induced by infection with the Colombian strain of T. cruzi.
The chronic infection of C57BL/6 mice with the Colombian strain of T. cruzi induces CCC,
which is characterized by heart injury with connexin-43 (Cx43) disorganization and fibronec-
tin (FN) deposition in the cardiac tissue and increased CK-MB activity in the serum [5, 18, 20].
Therefore, we tested the capacity of the homologous prime-boost rAdVax immunotherapy to
reverse heart injury. To this end, C57BL/6 mice were infected and all mice were analyzed at
120 dpi (pre-therapy), when groups were formed, and the prime-boost rAdVax immunization
protocol was initiated. A group of T. cruzi-infected mice was euthanized and the tissues were
collected (pre-therapy). At 160 dpi and 40 days post-therapy, all mice were analyzed for electri-
cal alterations, boosted and analyzed at 230 dpi, 110 days post-therapy (Fig. 3A). No difference
in survival rate was observed in T. cruzi-infected mice that received saline or rAdCtrl and all
mice in these groups were dead at 200 dpi (Fig. 3B). At 230 dpi, 87% of rAdVax-immunized
mice survived (13/15), compared with 0% of rAdCtrl-inoculated (0/14) and saline-injected
(0/14) mice (Fig. 3B). The surviving mice were analyzed at 230 dpi (110 days post-therapy) for
heart electrical abnormalities, sacrificed and analyzed for cardiac tissue alterations compared
with mice sacrificed at 120 dpi (pre-therapy). In post-therapy rAdVax-inoculated mice (at
230 dpi), there was a significant decrease in T. cruzi-induced splenomegaly (P< 0.01). Similar-
ly to pre-therapy (120 dpi) mice, low heart parasitism persisted in rAdVax-immunized mice
(Fig. 3C). In addition, pre-therapy and post-therapy parasites were rarely detected in the
circulating blood (110 ± 70.2 × 103 trypomastigotes/mL in pre-therapy vs. 22.8 ± 9.5 × 103
trypomastigotes/mL in rAdVax; P> 0.05). Nevertheless, immunotherapy with rAdVax sig-
nificantly reduced FN deposition in the cardiac tissue (Fig. 3D and 3E). Furthermore, Cx43 dis-
organization in the cardiac intercalary discs revealed as enhanced distance of Cx43-stained
junctions, a marker of cardiomyocyte injury [21], was significantly reversed in mice treated
with rAdVax compared with the pre-therapy condition (Fig. 3E). In addition, levels of CK-MB
activity in the serum were lower in post-therapy mice compared with pre-therapy mice
(Fig. 3F). Thus, these data support that immunotherapy with rAdVax during chronic T. cruzi
infection ameliorated electrical abnormalities and recovered heart tissue injury.
Recovering effects of rAdVax immunotherapy on heart tissue were
associated with reduced polyclonal and cytotoxic responses but
preserved parasite-specific IFNγ production
Next, we investigated whether the beneficial effect of the prime-boost immunotherapy with
rAdVax in chronically infected C57BL/6 mice was associated with reduction in the abnormal
presenting arrhythmias (ART), second-degree atrioventricular block (AVB2) and afflicted with ECG
alterations, at 150 dpi. The data are presented as the means ± SD of seven to ten mice per group. *P<0.05,
experimental groups compared with NI controls. ΨΨP< 0.01, rAdVax-immunized compared with saline-
injected T. cruzi-infected mice. §§P< 0.01, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-
infected mice.
doi:10.1371/journal.ppat.1004594.g001
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polyclonal activation observed in chronically infected mice and/or shift of the immune re-
sponse to a protective profile. To this end, chronically infected mice received the homologous
prime-boost vaccine rAdVax and were analyzed at 190 and 230 dpi, corresponding to 70 and
110 days post-therapy (Fig. 4A). As depicted in Fig. 4B, the potent IFNγ recall response after
Figure 2. rAdVax immunotherapy ameliorated electrical abnormalities of chronically T. cruzi-infected mice. (A) Chronically Colombian-infected mice
(120 dpi) were primed-boosted with 2 × 108 plaque-forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2
+rAdTS; rAdVax) and analyzed for electrocardiogram (ECG) abnormalities at 70 and 110 days post-therapy (dpt). (B) Heart rate (beats per minutes, bpm)
and P wave duration (per ms). The data are shown as the means ± SD per group of 7–8 mice. (C) Representative ECG register segments of sex- and age-
matched noninfected (NI) controls and T. cruzi-infected mice injected with saline or vaccinated with rAdCtrl or rAdVax at 160 dpi (40 days post-prime) and
230 dpi (110 dpt). (D) Summary of the group data from NI controls and chronically T. cruzi-infected mice injected with saline or vaccinated with rAdCtrl or
rAdVax, showing the frequency of mice presenting arrhythmias (ART), second-degree atrioventricular block (AVB2) and afflicted with ECG alterations.
* P<0.05, **P<0.01 and ***P<0.001, experimental groups compared with NI controls. # P<0.05, ##P<0.01 and ###P<0.001, rAdVax-immunized
compared with pre-therapy T. cruzi-infected mice. § P<0.05, §§P< 0.01 and §§§P<0.001, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-
infected mice.
doi:10.1371/journal.ppat.1004594.g002
Therapeutic Vaccine for Chronic Chagas Disease
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Figure 3. rAdVax immunotherapy recovered the injured heart tissue of chronically T. cruzi-infected
mice. (A) Chronically Colombian T. cruzi strain-infected mice were evaluated for heart injury markers
pre-therapy (120 dpi) or primed-boosted with 2 × 108 plaque-forming units (PFU) of rAdCtrl or a mixture of
108 PFU of each adenovirus vaccine preparation (rAdASP2+rAdTS; rAdVax). Mortality was recorded
until 230 dpi (110 days post-therapy; dpt), when the surviving mice were analyzed for heart injury markers.
(B) Kaplan-Meier curve representing the percentages of surviving mice (14–20 mice/group in two in-
dependent experiments). (C) Relative spleen weight (mg of spleen/g of body) and quantitative immuno-
histochemical staining (IHS) data for T. cruzi parasitism (nests/100 microscopic fields) in the heart tissue
of chronically infected mice (120 and 230 dpi, respectively, pre- and post-therapy). (D) IHS showing
Therapeutic Vaccine for Chronic Chagas Disease
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stimulation of mononuclear spleen cells with anti-CD3 plus anti-CD28, previously described
as a hallmark of chronically T. cruzi-infected mice [22], was reproduced in the present study in
the Colombian-infected rAdCtrl-immunized mice. In contrast, this response was abrogated by
rAdVax immunotherapy (Fig. 4B). Moreover, the intense anti-CD3 plus anti-CD28-triggered
lymphoproliferative response observed in total splenic T-cells from T. cruzi-infected mice in-
jected with rAdCtrl was also inhibited by rAdVax immunotherapy (Fig. 4C). Notably, the in-
creased anti-CD3 plus anti-CD28-triggered CD8+ T-cell proliferation observed during chronic
infection was also reversed by rAdVax inoculation (Fig. 4D), whereas CD8+ T-cell recognition
of the H-2Kb-restricted VNHRFTLV ASP2 peptide was preserved in rAdVax-immunized mice
(Fig. 4E).
Beneficial effect of rAdVax therapy was associated with reduced
frequency of degranulated CD107a+ CD8+ T-cells
Then, we evaluated the frequency of CD8+ T-cells expressing CD107a, a marker for T-cell de-
granulation used to evaluate CTL activity [23]. Ex vivo, the frequencies of CD8+ T-cells in the
spleen were similar in all studied groups (Fig. 5A, box). Compared with age-matched NI con-
trol mice, there is an increase in the proportions of CD8+ T-cells expressing CD107a in T.
cruzi-infected mice injected with rAdCtrl (Fig. 5A). Importantly, this increase in the frequency
of CD107a+ CD8+ T-cells was abrogated by the therapeutic rAdVax administration (Fig. 5A).
Further, when in vitro stimulated with VNHRFTLV ASP2 peptide there is a preferential re-
sponse of CD8+IFNγ+CD107a+ cells and CD8+CD107a+ cells in mice injected with rAdCtrl
(Fig. 5B). Therapeutic rAdVax administration significantly reduced the frequency of
CD8+IFNγ+CD107a+ cells and, moreover, diminished the frequency of CD8+CD107a+ cells
recognizing the VNHRFTLV ASP2 peptide (Fig. 5B).
The beneficial effect of the combined rAdVax therapy was associated
with a protective effector profile in heart tissue
It was previously demonstrated that perforin+ and IFNγ+ CD8+ T-cells play antagonistic roles
in the heart tissue of T. cruzi-infected mice [5]; therefore, we examined whether rAdVax im-
munization influenced the number of cytotoxic (Pfn+) and inflammatory (IFNγ+) cells com-
posing the chronic T. cruzi-induced myocarditis. All groups of chronically T. cruzi-infected
mice presented increased numbers of Pfn+ and IFNγ+ cells infiltrating the heart tissue com-
pared with age-matched NI controls (Fig. 6A). However, compared with rAdCtrl-injected
mice rAdVax-immunized mice showed reduced number of Pfn+ cells but similar number of
IFNγ+ cells infiltrating the cardiac tissue (Fig. 6A). Moreover, therapy with rAdVax (analysis
at190 dpi; 70 days post vaccine therapy) decreased the number of Pfn+ cells infiltrating the
heart tissue compared with mice pre-therapy (120 dpi). Interestingly, the IFNγ/Pfn ratio was
increased in rAdVax-immunized chronically infected mice (5.83) compared with rAdCtrl-
injected mice (3.20) and pre-therapy mice (2.09) (Fig. 6A, box). Compared with NI control
mice, a significant increase in IFNγmRNA expression was detected in the cardiac tissue
fibronectin (FN)-stained areas in representative cardiac tissue sections of noninfected (NI) controls and
chronically T. cruzi-infected mice pre- (120 dpi) and post-therapy (230 dpi; 110 dpt) with rAdVax. (E)
Quantification of the FN-stained area (%) and connexin 43 (Cx43)-containing gap junction distances
detected using IHS staining of heart tissue sections of NI controls or T. cruzi-infected mice pre- and post-
therapy with rAdVax. (F) Evaluation of CK-MB activity in the serum of NI controls and T. cruzi-infected
mice pre- and post-therapy with rAdVax. The data are presented as the means ± SD. ** P <0.01 and
***P <0.001, experimental groups compared with NI controls. # P <0.05 and ##P <0.01, rAdVax-
immunized compared with pre-therapy T. cruzi-infected mice.
doi:10.1371/journal.ppat.1004594.g003
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Figure 4. Shift of the immune response through rAdVax immunotherapy in chronically T. cruzi-infected mice. (A) Chronically Colombian-infected
mice were primed-boosted with 2 × 108 plaque-forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2
+rAdTS; rAdVax) and analyzed at the endpoints, as indicated. (B) Numbers of IFNγ-secreting cells in the spleens of immunized mice were determined using
ELISpot after 20 hours of stimulation with anti-CD3 plus anti-CD28. (C) Representative histograms showing the R1-gated CFSEhigh-based
lymphoproliferative response after 72 hours of stimulation with anti-CD3 plus anti-CD28. (D) Representative dot plot showing the R1-gated CFSELow-based
lymphoproliferative response after 72 hours of treatment with anti-CD3 plus anti-CD28. After stimulation, the spleen cells were stained with APC-conjugated
anti-CD8. Cycling CFSELowCD8+ cells were detected in gates R3, R4 and R5. (E) Numbers of CD8+IFNγ-secreting cells in the spleens of immunized mice
were determined by ELISpot using the H-2Kb-restricted VNHRFTLV peptide (3 and 10 μg/mL). The results represent three to five mice per experimental
group of non-infected (NI) controls and T. cruzi-infected mice immunized with rAdCtrl or rAdVax and analyzed at 190 dpi (70 days post-therapy). * P<0.05,
** P<0.01 and ***P<0.001, experimental groups compared with NI controls. † P<0.05, non-stimulated compared with stimulated condition in an
experimental group. § P<0.05, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-infected mice.
doi:10.1371/journal.ppat.1004594.g004
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obtained from infected mice before (at 120 dpi) and after (at 190 dpi) immunotherapy with
rAdCtrl and rAdVax (Fig. 6B). Remarkably, vaccination with rAdVax significantly increased
the expression of IFNγmRNA in comparison with rAdCtrl-immunized and pre-therapy mice
(Fig. 6B). Therefore, these data support that rAdVax shaped the IFNγ/Pfn balance in the
chronic T. cruzi-induced myocarditis favoring the presence of IFNγ+ cells and the production
of IFNγ. Compared with pre-therapy chronically infected mice, rAdVax-inoculated mice ex-
hibited no alterations in the serum concentrations of the inflammatory cytokines IL-1α, IL-2,
IL-4, IL-5, IL-10, IL-17 and TNF (S4A and S4B Fig.). Interestingly, rAdVax immunization sig-
nificantly increased IFNγ levels compared with pre-therapy T. cruzi-infected mice (S4A Fig.
and Fig. 6C).
rAdVax therapy during chronic T. cruzi infection was associated with
reduced NO levels in the serum and iNOS in the heart tissue
Lastly, the NO/ iNOS pathway has been associated with heart injury and CCC severity in
chronic T. cruzi infection [18, 24]. The kinetic study of serum NOx levels in T. cruzi-infected
mice revealed that during acute infection, NOx concentrations in the serum (S5A Fig.) paral-
leled parasitemia (at 42–45 dpi) and higher levels of CK-MB activity in the serum (S5B Fig.).
After parasite control, a reduction in NOx levels was detected; however, during the chronic
Figure 5. Reduced frequency of CD107a+CD8+ T-cells in chronically T. cruzi-infectedmice subjected
to rAdVax immunotherapy. Chronically Colombian-infected mice (120 dpi) were primed-boosted with
2 × 108 plaque-forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation
(rAdASP2+rAdTS; rAdVax), as experimental scheme in Fig. 2. The spleen cells were analyzed using flow
cytometry at 190 dpi (70 days post-therapy). (A) Frequencies of total CD8+ T-cells (box) and mono and
multifunctional IFNγ−CD107a−, CD107a+, IFNγ+ or IFNγ+CD107a+ CD8+ T-cells (pie charts). (B) Graphs
showing the frequencies of IFNγ+, IFNγ+CD107a+ and CD107a+ CD8+ T-cells after 72 hours of in vitro
stimulation with VNHRFTLV ASP2 peptide. The results represent three to five mice per experimental group.
§§P< 0.01 and §§§P<0.001, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-infected mice.
doi:10.1371/journal.ppat.1004594.g005
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phase of infection, NOx levels were increased and paralleled the levels of CK-MB activity in the
serum (S5B Fig.). Therefore, we assessed the effect of rAdVax therapy in chronically infected
mice on the concentration of serum NOx and the expression of iNOS/NOS2 in cardiac tissue.
All chronically T. cruzi-infected mice shown increased NOx levels in the serum compared with
age-matched NI controls (Fig. 7A and 7B). Interestingly, in comparison with rAdCtrl-inoculat-
ed mice rAdVax-immunized mice (at 190 dpi; 30 days after the boost immunization with rAd-
Vax) showed a significant decrease in the concentrations of NOx in the serum (Fig. 7A).
Furthermore, a kinetic study revealed a significant reduction in the levels of NOx in the serum
of rAdVax-immunized mice (190 dpi; 30 days after the boost) in comparison with rAdCtrl
mice. Further, reduction of serum NOx level was more prominent after two doses of rAdVax
Figure 6. rAdVax immunotherapy increased IFNγ expression in the heart tissue and in the serum.
Chronically Colombian-infected mice were immunized with 2 × 108 plaque-forming units (PFU) of rAdCtrl or a
mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2+rAdTS; rAdVax) in a prime-boost
homologous protocol. The hearts and sera of noninfected (NI) controls, infected mice pre-therapy (120 dpi)
and rAdCtrl- or rAdVax-immunized mice were collected at 190 dpi (70 days post-therapy; dpt) or 230 dpi
(110 dpt). (A) immunohistochemical staining (IHS) quantification of Pfn+ and IFNγ+ cells in the cardiac tissue;
relative ratios of IFNγ+ /Pfn+ cells are shown in the upper-box. (B) Expression of IFNγmRNA in the heart
tissue detected by qRT-PCR. The data are expressed as the mRNA fold-increase in relation to NI controls.
(C) Concentration of IFNγ in the serum of NI controls and T. cruzi-infected pre-therapy and rAdVax-
immunized mice. The results represent three to five mice per experimental group. * P<0.05, ** P<0.01 and
***P<0.001, experimental groups compared with NI controls. # P<0.05 and ##P<0.01, rAdVax-immunized
compared with pre-therapy T. cruzi-infected mice. § P<0.05 and §§§P<0.001, rAdVax-immunized compared
with rAdCtrl-injected T. cruzi-infected mice.
doi:10.1371/journal.ppat.1004594.g006
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therapy, (230 dpi; 70 days after the boost immunization with rAdVax) (Fig. 7B). Moreover,
there was a significant decrease in the levels of NOx in the serum of mice that received two
doses of rAdVax compared with pre-therapy mice (Fig. 7B). Importantly, the expression of
iNOS/NOS2 mRNA was significantly reduced in the cardiac tissue of chronically infected mice
immunized with two doses of rAdVax, in comparison with pre-therapy mice (Fig. 7C).
Discussion
One of the greatest challenges in chronic Chagas’ heart disease is to develop therapies that
improve prognosis and, even, reverse cardiac injury. Here we used the recombinant Type 5 ad-
enovirus carrying sequences of the trans-sialidase family ASP2 and TS proteins in a homolo-
gous prophylactic or therapeutic prime-boost protocol aiming at inhibiting development and
progression or reversing chronic T. cruzi-induced heart damage. The prophylactic rAdVax
immunization successfully reduced acute heart parasitism and cardiomyocyte damage and de-
creased the frequency of mice afflicted by chronic electrical abnormalities due to challenge
with the Colombian T. cruzi Type I strain. Moreover, the therapeutic administration of
rAdASP2+rAdTS to chronically Colombian-infected mice afflicted by CCC decreased cardiop-
athy progression and, remarkably, reversed electrical abnormalities and heart tissue injury.
Further investigation showed that the clinical beneficial effects were associated with reduction
of the prototypical T. cruzi-induced polyclonal T-cell proliferation and, moreover, with
reprogramed immune responses, both systemically and in the heart tissue, favoring IFNγ
production and decreasing cytotoxic activity, NOx production and iNOS/NOS2 expression in
T. cruzi infection.
The prophylactic administration of rAdASP2, rAdTS or rAdASP+rAdTS combined
vaccines in prime-boost protocols elicited humoral and cellular immune response [16, 17].
Vaccination of C57BL/6 (H-2b) with either rAdASP2 or rAdTS increased survival frequency,
but only the combined rAdASP+rAdTS inoculum induced complete and long lasting protec-
tion against a challenge with the Y T. cruzi Type II strain parasites [16]. Further, the combined
rAdASP+rAdTS vaccination of A/Sn (H-2a) mice was shown to be protective against a chal-
lenge with the Y and Colombia T. cruzi Type II strains [17]. In addition, a heterologous plas-
mid DNA prime-rAdHu5 boost vaccination carrying the ASP2 sequence generated a stable
pool of protective long-lived effector memory CD8+ T-cells specific for T. cruzi [25]. Altogeth-
er, ASP2 and TS are shown to be suitable candidate antigens to trigger both humoral and
cellular protective immunity, which are critical requisites for an immunoprophylactic protein
vaccine that is presented as a pure polypeptide or within delivery vectors (plasmid, adenovirus)
[13, 14, 16, 17, 25–28].
Based on the demonstration that homologous rAdVax prime-boost scheme induced anti-
bodies and efficient IFNγ-producing and CTL CD8+ T-cell effectors, corroborating previous
data adopting different vaccination strategies [16, 17, 27], we hypothesized that rAdVax would
also induce protective response to T. cruzi Type I strain-induced CCC. To test this assumption,
we used a low-dose (100 bt) inoculum of the Colombian strain, facilitating acute phase survival
but inducing CCC [5, 18, 19]. Importantly, the prophylactic vaccination of C57BL/6 mice with
rAdVax significantly reduced heart parasitism during the acute phase, which remained low
during chronic infection. Moreover, prophylactic therapy with rAdVax significantly precluded
heart abnormalities (including ARTs and AVBs), major clinical signs of Chagas’ heart disease
[1]. Further, prophylactic therapy with rAdVax reduced the acute heart parasitism and cardio-
myocyte damage induced by the CL-Brener T. cruzi Type VI strain. Importantly, our data sup-
port that immune responses triggered to antigen of a T. cruzi strain may allow resistance in a
broad manner. Notably, human populations exhibit a powerful innate and acquired immune
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Figure 7. rAdVax immunotherapy modulated serumNOx levels and cardiac iNOS expression in
chronically T. cruzi-infected mice.Chronically Colombian-infected mice were immunized with 2 × 108
plaque-forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation
(rAdASP2+rAdTS; rAdVax) in a prime-boost homologous protocol. The hearts and sera of noninfected (NI)
controls, infected mice pre-therapy (120 dpi) and rAdCtrl- or rAdVax-immunized mice were collected at
different time-points, accordingly with the experimental design. (A) Concentration of NOx in the serum NI
controls and infected mice at 190 dpi (70 days post-therapy; dpt). (B) Concentration of NOx in the serum of NI
controls, chronically T. cruzi-infected mice pre-therapy (at 120 dpi) and after immunization with rAdCtrl or
rAdVax: 1 dose (at 160 dpi; 40 dpt), 2 doses (at 190 dpi; 70 dpt) and at the endpoint (post-therapy; at 230 dpi;
110 dpt). (C) Relative quantification of iNOSmRNA expression quantified using qRT-PCR in the heart tissue
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response to T. cruzi during acute infection, independently of the parasite strain, facilitating the
development of the chronic phase of infection [1, 3, 15]. Therefore, the results of the present
study corroborate our previous data showing that an association of different parasite antigens
delivered in an appropriated protocol might have a beneficial impact on Chagas infection pro-
phylaxis. Particularly considering vaccines as a strategy for decreasing parasite load in reser-
voirs, such as dogs, rAdVax may be a powerful tool to inhibit the domestic and peri-domestic
cycle of T. cruzi, regardless the parasite strain faced in the natural infection [6]. Moreover, the
prophylactic administration of rAdVax precluded relevant aspects of chronic Chagas’ heart
disease [1], therefore surging as a strategy to improve prognosis.
Millions of people are infected with T. cruzi. Among these, 20–40% will manifest the cardiac
form of CD, with mild to severe signs and symptoms and premature death, within 10–30 years
after infection [1, 7]. Therefore, therapeutic vaccines may emerge as a tool to improve progno-
sis of chronic patients. The present study is the first to show that a vaccine preparation may
abrogate, delay progression and, moreover, reverse T. cruzi-induced ECG alterations, including
bradycardia, ARTs and AVB2. These electrical abnormalities represent important features
detected in cardiophatic chagasic patients [1] recapitulated in the model of chronically T.
cruzi-infected mice used [5, 18,19]. Increased levels of CK-MB activity in serum, a biomarker
of cardiomyocyte lesions [29], that is consistently detected in chronically infected mice [5, 20],
was also reversed by rAdVax immunization of chronically infected mice. Furthermore, two
main heart tissue injuries of chronically Colombian-infected mice, i.e. enhanced FN deposition
and Cx43 disorganization and loss [18, 20], were reversed through therapeutic immunization
with rAdVax. Chronic cardiac fibrosis, revealed as deposition of extracellular matrix compo-
nents including FN, is associated with CD severity in patients [30, 31], non-human primates
[24] and mice [18]. Here we describe that chronically infected mice show overdeposition of FN
in the cardiac tissue, which is reversed by therapeutic administration of rAdVax. In benznida-
zole-treated mice, reduced heart parasitism is accompanied by decreased FN deposition and
fibrosis [32]. Furthermore, therapeutic intervention in the inflammatory axis with the CCR1/
CCR5 antagonist Met-RANTES [20] and the anti-tumor necrosis factor Infliximab antibody
also reduced FN deposition in the cardiac tissue of chronically Colombian-infected mice [19],
supporting that this a reversible feature of CCC. The disorganization and loss of Cx43, the
most abundant ventricular gap junction protein, is associated with arrhythmogenic disease
[21]. This is another important biomarker of heart tissue damage associated with severity of
electrical abnormalities in T. cruzi-infected mice [18]. Moreover, cardiac Cx43 expression is
down-regulated in patients with CCC [33] and in cardiopathic compared with indeterminate
chronically infected rhesus monkeys [24]. The intensity of C43 loss was also associated with
disease severity in models of severe and mild CCC [18]. Therefore, a major beneficial effect of
the immunotherapy with rAdVax was the restoration of Cx43 expression in the heart of chron-
ically infected mice. Taken together, these data support the idea that T. cruzi-induced chronic
heart damage can be ameliorated after appropriated interference, which may consist of target-
ing the parasite [32] or other putative pathogenic factors, such as chemotactic [20] or inflam-
matory [19] mediators. Hence, these findings reinforce the idea that vaccination with rAdVax
(rAdTS+rAdASP2) is a promising tool for intervention in patients affected by CCC.
of NI controls and chronically T. cruzi-infected mice pre-therapy (at 120 dpi) and post-therapy with rAdVax (at
230 dpi; 110 dpt). The results represent three to seven mice per experimental group. * P<0.05, ** P<0.01
and ***P<0.001, experimental groups compared with NI controls. # P<0.05, rAdVax-immunized compared
with pre-therapy T. cruzi-infected mice. §P< 0.05 and §§P<0.01, rAdVax-immunized compared with rAdCtrl-
injected T. cruzi-infected mice.
doi:10.1371/journal.ppat.1004594.g007
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Taken together, these data encouraged further studies on the mechanisms by which rAdVax
administration exerts beneficial effects in chronically T. cruzi-infected mice. Prophylactic rAd-
Vax administration efficiently reduced acute heart parasitism, corroborating previous attempts
using prophylactic vaccines carrying different immunogenic constructions, formulations and
vectors that induce effective vaccines that reduce parasitism [8, 9, 16, 17, 27]. Further, prophy-
lactic rAdVax also reduced the number of CD8+ cells infiltrating the heart tissue. There is a re-
lation between parasite load and CD8+ cell infiltrating the heart tissue [34]. Therapeutic
rAdVax immunization of chronically infected mice had no significant effect on the already low
parasite load in the heart tissue. There is no relation between parasite load and myocarditis in-
tensity in the chronic phase of infection [35], when parasites are mostly intracellular and,
therefore, less accessible to effector immune response. Recently, we showed that both IFNγ+
and Pfn+ inflammatory cells present in the cardiac tissue contribute to parasite control; howev-
er, Pfn+ cells also contribute to tissue injury [5]. Importantly, the number of Pfn+ cells was re-
duced after rAdVax immunization of chronically infected mice, associated with improvement
of heart ECG abnormalities and cardiac damage. Undoubtedly, one cannot rule out the possi-
bility that factors of the immune response, as cytokines not modulated by rAdVax immuniza-
tion as TNF, shown to promote parasite growth [36], also contribute to maintain low parasite
load in vaccinated mice. Nevertheless, more than parasite load and intensity of myocarditis,
the total scenario, which also includes effector cells and cytokine milieu contributing to immu-
nological unbalance, may play crucial role in chronic Chagas’ heart disease pathogenesis [19,
20, 37].
Splenomegaly, associated with increased cellularity, is a hallmark of chronic experimental
CD [5, 22]. Reversion of splenomegaly in rAdVax-treated chronically T. cruzi-infected mice
was the first indication that this therapeutic tool interferes with parasite-triggered immunologi-
cal abnormalities. Chronically T. cruzi-infected mice show an intense proliferative response of
CD8+ T-cells and increased frequency of IFNγ-producing CD8+ T-cells after polyclonal stimu-
lation with anti-CD3 plus anti-CD28 [22]. Here we reproduced this abnormality in rAdCtrl-
injected chronically Colombian-infected mice. Importantly, CD8+ T-cell proliferation and
IFNγ production induced by polyclonal activation with anti-CD3 plus anti-CD28 were signifi-
cantly reduced in rAdVax-immunized mice. However, the T. cruzi-specific IFNγ-producing
CD8+ T-cells present in chronically T. cruzi-infected mice were preserved in these mice.
Therefore, the therapy of chronically infected mice with rAdVax in a prime-boost homologous
protocol reduced the T. cruzi-induced chronic polyclonal activation of CD8+ T-cells, but pre-
served the potentially beneficial IFNγ-producing CD8+ T-cells [5].
Previous studies with vaccines have provided evidence that prophylactic vaccines using
ASP2 and/or TS constructs in different delivery tools stimulate both IFNγ producers and cyto-
toxic CD8+ T-cells, which play a protective role after challenge with virulent T. cruzi strains
[16,17,27,28,38,39]. Our results demonstrated that therapeutic homologous prime-boost vacci-
nation with rAdVax significantly reduced the frequency of ex vivo freshly isolated and
VNHRFTLV ASP2 peptide-specific CD8+CD107a+ T-cells. CD107a marks degranulation,
paralleling the cytotoxic activity of T-cells [23]. Recent data have suggested that the induction
of multifunctional CD8+CD107a+ T-cells co-expressing IFNγmight be beneficial against acute
T. cruzi infection [40]. The data obtained in the present study, however, suggest that the persis-
tence of CD107a+ T-cells during chronic infection might be detrimental. Indeed, the down-
modulation of the frequency of CD8+CD107a+ T-cells paralleled the improvement of heart
ECG abnormalities and tissue injury in rAdVax-immunized mice, thereby reinforcing the idea
that cytotoxic CD8+ T-cells are detrimental in chronic T. cruzi infection [5]. These findings led
us to inquire whether this effect of rAdVax therapy impacted the immunological status of the
cardiac tissue. Indeed, rAdVax administration to chronically infected mice reduced the number
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of Pfn+ cells colonizing the cardiac tissue, whereas the numbers of IFNγ+ cells persisted elevat-
ed. Truly, the IFNγ+/Pfn+ cells ratio was significantly increased in rAdVax-inoculated mice.
Furthermore, the expression of IFNγmRNA in the cardiac tissue was significantly increased in
rAdVax-immunized mice in comparison with rAdCtrl-injected and pre-therapy mice. Also, a
remarkable increase in IFNγ levels in serum was detected in rAdVax-immunized chronically
infected mice. Importantly, systemically and in heart tissue increased IFNγ expression paral-
leled the amelioration of ECG abnormalities and cardiac tissue damage. Again, these results are
consistent with the idea that IFNγ plays a beneficial role in the heart tissue injury during chaga-
sic infection [5]. This, immunization with vaccine constructs carrying the coding sequences of
ASP2 and TS parasite antigens in an appropriate delivery system shifted the immune response
to a less detrimental (cytotoxic) profile and/or to a more beneficial (IFNγ) status, which may
contribute to improve the experimental Chagas’ heart disease. Altogether, these data support
the idea that parasite-triggered immunological unbalance promotes Chagas’ heart disease [5,
19,41, 42].
Chronic chagasic cardiomyopathy is undoubtedly the most severe form of CD [1]. The
pathogenic factors leading to CCC remain largely unknown; therefore, the comprehension of
these factors and the identification of biomarkers of prognosis and severity might contribute to
the development of vaccines and more efficient therapies. In this context, studies have shown
that NO levels in serum parallels CCC severity in humans [43] and non-human primates [24].
Indeed, here we demonstrated that in chronic experimental CD the levels of NOx paralleled
CK-MB activity in serum, reinforcing the idea that NOx levels is associated with cardiomyocyte
lesion [18,24]. In T. cruzi infection, NO is produced via iNOS/NOS2 in a wide range of cells
and tissues and acts as an important trypanocidal agent [44]; however, NO can be cytotoxic
and destructive to tissues when produced at high concentrations and for long periods [43].
Chagas’ heart disease relies on a complex host-parasite interrelationship. In this sense, it has
been shown that T. cruzi persistence can serve as a stimulus for continuous iNOS/NOS2 ex-
pression in cardiac tissue and, consequently, a large amount of NO might accumulate in this
tissue [45]. Hence, an increased expression of iNOS/NOS2 in heart tissue and enhanced supply
of NO could lead to cardiomyocyte lesion and heart injury [24]. In the present study, chronic
T. cruzi infection (at 120 dpi) was accompanied by a significant increase in serum NOx levels
and the enhanced expression of iNOS/NOS2 in heart tissue, both paralleling the heart tissue in-
jury (Cx43 loss and FN overdeposition) and electrical alterations. Consistently, NOx levels in
serum and iNOS/NOS2 expression in cardiac tissue were successfully reduced after prime-
boost therapy with rAdVax, paralleling amelioration of ECG abnormalities and heart tissue
damage. Thus, delivery of ASP2 and TS genes in the form of rAd constructs emerges as a ratio-
nal alternative tool to reprogram immune responses to a less detrimental and a more protective
profile (particularly in heart tissue), interrupt progression and recover tissue injury in chronic
Chagas’ heart disease.
Here we brought insights on the biological processes contributing to beneficial effects of the
prime/boost with rAdVax on clinical signs of chronic experimental CD. However, the molecu-
lar mechanisms for the immunological reprograming mediating the effects of our vaccine con-
structions and regimen of administration were not addressed in the present study. Our data
support that rAdVAx reverses several immunological abnormalities (polyclonal T-cell activa-
tion, increased frequency of CD107a+CD8+ T-cells, accumulation of Pfn+ cells in the heart tis-
sue and high NO levels in the serum), thus it is conceivable that distinct molecular mechanism
may take part in the reprogramming of these biological alterations, opening a new avenue to
be explored.
Lastly, CD is a major public health problem in Latin America; therefore, a vaccine would be
an important tool to improve the control of CD [46] and, mainly, to interfere with the outcome
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of CD. Here we propose the use of a recombinant AdHu5-based vaccine carrying ASP2 and TS
T. cruzi sequences to decrease acute parasite load and prevent CCC and as an alternative to re-
program the immunological unbalance in chronically infected individuals to delay progression
and, potentially, reverse prototypical pathological aspects of CCC. We consider that the main
theoretical barriers (safety and immunogenicity) to use recombinant AdHu5-based ASP2/TS
vaccine in chronic chagasic patients were recently overcame. Indeed, vaccine constructs for
HIV and tuberculosis using recombinant AdHu5 as vector enlightened our knowledgement
revealing that the vaccine regimen was safe and had an acceptable side-effect profile [47].
Moreover, the widely perceived negative effect of preexisting anti-AdHu5 immunity may not
be universally applied to all AdHu5-based vaccines. Preexisting neutralizing antibodies did not
affect the immunogenicity of an AdHu5-based malaria vaccine in humans [48]. Further, an
AdHu5-vectored vaccine engineered to express the immune dominantM. tuberculosis antigen
Ag85A was shown to be safe and robustly immunogenic, supporting a lack of correlation be-
tween preexisting anti-AdHu5 neutralizing antibody titers and the magnitude of vaccine-in-
duced T-cell activation [49]. Therefore, the AdHu5-based ASP2/TS therapeutic vaccine
administered either alone or combined with trypanocidal drugs as benznidazole [1] or target-
based adjuvants as rapamycin [50], might improve the prognosis of CCC, providing a new ap-
proach for the development of useful protocols to treat CD patients. Therefore, the results ob-
tained here demonstrate that the development of a successful vaccine for CD is not beyond
reach [2,7]. However, one cannot ignore that with success will come the economic barriers to
produce and deliver a vaccine against a neglected disease. Further, the extemporaneous cam-
paigns nurturing refractivity to vaccines may emerge as a new challenge to be surpassed.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimen-
tation (http://www.cobea.org.br/) and the Federal Law 11.794 (October 8, 2008). The Institu-
tional Committee for Animal Ethics of Fiocruz (CEUA-Fiocruz-L004/09) and the Brazilian
Biosafety National Committee (CQB/CTNBio-105/99) approved all experimental procedures
used in the present study. The Experimental Animal Facility is fully accredited by the National
Technical Commission on Biosafety (CTNBio; last notification, October 27, 2010). All pre-
sented data were obtained from four (INCTV1-4) independent experiments (Experiment
Register Books #3 and #4, LBI/IOC-Fiocruz).
Experimental infection
Mice obtained from the animal facilities of the Oswaldo Cruz Foundation (CECAL/Fiocruz,
Rio de Janeiro, Brazil) were housed under specific pathogen-free conditions in a 12-h light-
dark cycle with access to food and water ad libitum. Five- to seven-week-old female C57BL/6
(H-2b) mice were intraperitoneally (i.p.) infected with 100 blood trypomastigotes (bt) of the
Colombian T. cruzi Type I strain or with 1000 bt of the CL-Brener T. cruzi Type VI strain
[15] that had been prepared by passage through C57BL/6 every 35 or 10 days, respectively.
Parasitemia was used as a parameter to establish acute and chronic phases [5] and mortality
was recorded weekly. Sex- and age-matched noninfected (NI) controls were analyzed in paral-
lel. Accordingly to experimental designs, groups of mice were sacrificed under anesthesia
(100mg/Kg ketamine associated with 5mg/Kg xylazine chloride).
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Recombinant adenovirus construction and immunization
The construction of the replication-deficient human Type 5 recombinant adenoviruses carry-
ing the Escherichia coli β-galactosidase (rAdCtrl), the mouse Ig k chain SP fused to the ASP2
1–694 amino acid coding sequence (rAdASP2) and the signal peptide and catalytic domain
amino acid 34–678 of TS (rAdTS) coding sequences of the Y T. cruzi strain have been previous-
ly reported [16]. Mice were inoculated subcutaneously (s.c.) in the tail base with 100 μL of viral
suspension comprising apyrogenic saline (BioManguinhos, Brazil) supplemented with 1% nor-
mal mouse serum (Sigma, USA) containing 2 × 108 plaque-forming units (PFU) of rAdLacZ or
a mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2+rAdTS). The mice
were immunized twice at four- to six-week intervals, as shown in the scheme of the figures. As
experimental groups were analyzed at different moments, we associated the colors of the ar-
rows indicating the moments of analyses in the experimental schemes with the colors of the
bars representing the results of the analyzed groups in the figures. Additionally to experiments
to analyze the immune response, in two experiments mice were immunized as described above
and death was weekly registered. The results of these experiments were combined to establish
survival curve.
Reagents and antibodies
For T-cell functional assays, we used the H-2Kb-restricted VNHRFTLV peptide from ASP2
[13] synthesized by GenScript USA Inc. (USA). For in vivo cytotoxicity assays, target and con-
trol cells were tagged with the fluorogenic dye carboxyfluorescein diacetate succinimidyl ester
(CFSE, Molecular Probes, USA). For lymphoproliferation assays, we used a CFSE-based cell
tracer for flow cytometry (CellTrace Cell Proliferation kit, Invitrogen, USA). For immunohis-
tochemical staining (IHS), the polyclonal antibody against T. cruzi antigens and supernatants
containing anti-mouse CD8a (clone 53–6.7) and anti-mouse CD4 (clone GK1.5) were pro-
duced in our laboratory (LBI/IOC-Fiocruz, Brazil). Other antibodies included an anti-F4/80
polyclonal antibody (Caltag, USA), polyclonal rabbit anti-connexin 43 (Cx43) (Sigma, USA),
polyclonal rabbit anti-mouse fibronectin (FN) (Gibco-BRL, USA), biotinylated anti-rat immu-
noglobulin (Dako, Denmark) and biotinylated anti-rabbit immunoglobulin and peroxidase-
streptavidin complex (Amersham, UK). The monoclonal antibodies anti-mouse Pfn (CB5.4,
Alexis Biochemicals, USA) and anti-IFNγ (R4-6A2, BD PharMingen, USA) produced in rat
were also used in IHS. For flow cytometry, PECy7-anti-CD3 (clone 17A2), APC-conjugated
anti-mouse CD8a (clone 53–6.7), PerCP-anti-CD4 (clone GK1.5) and PECy-7-conjugated
anti-IFNγ (clone XMG1.2) were purchased from BD Pharmingen (USA). PE-conjugated anti-
CD107a (clone eBIO1D4B) was obtained from eBioscience. Endotoxin-free purified anti-CD3
(clone 145-2C11) and anti-CD28 (clone 37.51) were purchased from Southern Biotech (USA).
Appropriate controls were prepared by replacing the primary antibodies with the correspond-
ing serum, purified immunoglobulin or antibody isotype. All antibodies and reagents were
used according to the manufacturers’ instructions.
Antibody detection using ELISA
Recombinant TS or ASP2 proteins were produced in E. coli and total antibodies (IgM+IgG)
against these proteins were detected using an enzyme-linked immunosorbent assay (ELISA) as
previously described [51]. Each serum sample was serially diluted (1:200, 1:400 and 1:800) for
analysis. The optical density (OD) at 405 nm higher than twice the OD detected in serum of
non-immunized mice (in this case higher than 0.1) was considered positive for antibody detec-
tion. The results are presented as the mean OD of six to eight mice per group.
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IFNγ enzyme-linked immunospot (ELISpot) assay
The ELISpot assay for the enumeration of IFNγ-producing cells was performed in triplicate as
previously described [39]. Plates were coated with anti-mouse IFNγ (clone R4-6A2; BD Phar-
Mingen, USA) antibody diluted in PBS (5 μg/mL). Antigen-presenting cells were primed with
total T. cruzi antigens (10 μg/mL) for 30 minutes at 37°C. Concanavalin A (ConA, 5 μg/mL)
was used as a mitogenic stimulant. After incubation, the freshly isolated splenocytes were seed-
ed at 5 × 105 cells/well and incubated with the ASP2 H-2Kb-restricted VNHRFTLV peptide
[13] for 20 hours at 37°C and 5% CO2. Biotin-conjugated anti-mouse IFNγ antibody (clone
XMG1.2; BD PharMingen, USA) was used to detect the captured cytokines. Spots were re-
vealed after incubation of the samples with a solution of alkaline phosphatase-labeled streptavi-
din (BD PharMingen, USA) and a solution of NBT (Sigma, USA) and BCIP (Sigma, USA) in
Tris buffer (0.9% NaCl, 1% MgCl2, 1.2% Tris in H2O). The mean number of spots in triplicate
wells was determined for each experimental condition and the number of specific IFNγ-secret-
ing T-cells was calculated by estimating the stimulated spot count/106 cells using a CTL OHIm-
munoSpot A3 Analyzer (USA).
CFSE-based lymphoproliferative response
The lymphoproliferative response was assessed as described previously [5]. Briefly, spleens
were removed from NI or T. cruzi-infected vaccinated mice and single-cell suspensions of
splenocytes were prepared. The red blood cells were lysed using ACK buffer (Sigma, USA)
and mononuclear cells were labeled with CFSE at a final concentration of 7 μM (CFSEhigh) or
0.5 μM (CFSElow). The cells were incubated in RPMI medium supplemented with 10% SBF in
the presence of anti-CD3 and anti-CD28 (3 μg/mL) or 2.5 μM of the VNHRFTLV ASP2 pep-
tide for 72 hours at 37°C and 5% CO2. CFSE
high cells were washed and fixed with 1.0% parafor-
maldehyde. CFSElow cells were washed and labeled with APC-conjugated anti-CD8 antibody
as described above and fixed using 1.0% paraformaldehyde. All samples were acquired using a
Beckman Coulter CyAn 7 Color flow cytometer (Fullerton, CA, USA) and analyzed using the
Summit v.4.3 Build 2445 program (Dako, Denmark).
In vivo cytotoxicity assay
For the in vivo cytotoxicity assays, spleens collected from naïve C57BL/6 mice were treated
with ACK buffer (Sigma, USA) to lyse the red blood cells. The cells were divided into two pop-
ulations and labeled with the fluorogenic dye CFSE (Molecular Probes, USA) at a final concen-
tration of 10 μM (CFSEhigh) or 0.1 μM (CFSElow). CFSEhigh cells were coated with 2.5 μM of the
VNHRFTLV ASP2 peptide [13] for 40 minutes at 37°C. The CFSElow cells remained uncoated.
Subsequently, the CFSEhigh cells were washed and mixed with equal numbers of CFSElow cells
before intravenous injection (1–2 × 107 cells per mouse) into C57BL/6 recipients sedated with
diazepam (20 mg/Kg). Spleen cells were collected from the recipient mice at 20 hours after
adoptive cell transfer as indicated in the figure legends and fixed using 1.0% paraformaldehyde.
All samples were acquired using a Beckman Coulter CyAn 7 Color flow cytometer (Fullerton,
CA, USA) and analyzed using the Summit v.4.3 Build 2445 program (Dako, Denmark). The
percentage of specific lysis was determined using the following formula:
1 ð% CFSE
highinfected= % CFSElowinfectedÞ
ð%CFSEhighNI=% CFSElowNIÞ
 
 100%
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Immunohistochemistry
The mice were euthanized under anesthesia and their hearts were removed, embedded in tis-
sue-freezing medium (Tissue-Tek, Miles Laboratories, USA) and stored in liquid nitrogen. The
phenotypes of the inflammatory cells (CD4+, CD8+, F4/80+ ), IFNγ+ and Pfn+ cells colonizing
the heart tissue and the T. cruzi parasitism were characterized and analyzed as previously de-
scribed [5]. The FN- and Cx43-positive areas in 25 fields (12.5 mm2) per section (three sections
per heart) were evaluated using a digital morphometric apparatus as previously described [20].
The resulting images were digitized using a color view XS digital video camera adapted to a
Zeiss microscope and analyzed using AnalySIS AUTO software (Soft Imaging System, USA).
The data are presented as the percent positive area in the heart, the distance (μm) between
stained gap junctions or the numbers of parasite nests or cells per 100 microscopic fields
(400×).
Detection of cardiac muscle creatine-kinase isoform
The activity of the creatine kinase cardiac MB isoenzyme (CK-MB) was measured as a cardio-
myocyte lesion marker [29] using a commercial CK-MB Liquiform kit (Labtest, Brazil) accord-
ing to the manufacturer’s recommendations, as previously adapted for mouse samples [5].
Flow cytometry analysis
The spleens were minced and the red blood cells were removed using lysis buffer (Sigma,
USA). The splenocytes were labeled and events were acquired using a CyAn-ADP Analyzer
(Beckman Coulter, USA). The data were analyzed using the Summit v.4.3 Build 2445 program
(Dako, USA) as described elsewhere [5].
Phenotype of VNHRFTLV ASP2 peptide-stimulated CD8+ T-cells
The VNHRFTLV ASP2 peptide-specific response was assessed as described previously [5].
Briefly, spleens were removed and processed as described above. The cells were incubated in
RPMI medium supplemented with 10% SBF in the presence of 2.5 μM of the VNHRFTLV
ASP2 peptide for 72 hours at 37°C and 5% CO2. Cells were washed, processed and analyzed for
flow cytometry as described above.
Electrocardiogram (ECG) registers
The mice were sedated with diazepam (10 mg/kg) and transducers were placed subcu-
taneously (DII). The traces were recorded for 2 minutes using the digital Power Lab 2/20 Sys-
tem connected to a bio-amplifier at 2 mV for 1 second (PanLab Instruments, Spain). The filters
were standardized to 0.1–100 Hz and the traces were analyzed using Scope software for
Windows V3.6.10 (PanLab Instruments, Spain). ECG parameters were analyzed as previously
described [5].
Cytokine quantification
Cytokines (IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, GM-CSF, TNF, IFNγ) were detected in
serum using the commercial Th1/Th2 10plex FlowCytomix kit (MNS820FF; Bender MedSys-
tems Inc., Austria) according to the manufacturer’s instructions. The samples were assayed
with suitable controls provided by manufacturer for the construction of standard curves. The
fluorescence produced by the beads was measured on a FACSCalibur flow cytometer (BD, Bio-
sciences, USA) and analyzed using the software contained in the kit.
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NO quantification
Nitrate and nitrite (NOx) were determined to estimate the nitric oxide (NO) levels in the
serum samples using Griess reagent and vanadium chloride III; a standard curve of 0.8 to
100 mMNaNO2 and NaNO3 was prepared as described elsewhere [24].
Real-time quantitative RT-PCR for IFNγ and iNOSmRNA
For real-time quantitative RT-PCR (RT-qPCR), the mice hearts were harvested, washed to re-
move blood clots, weighed and frozen in RNAlater (#AM7021, Life Technologies, USA). Total
RNA (for gene expression studies) was extracted using TRI-Reagent (Sigma, USA). All reverse
transcriptase reactions were performed using a SuperScript III Kit (# 18080-051) and RT-
qPCR was performed using TaqMan gene expression assays for IFNγ (#Mm01168134_m1), in-
ducible NO synthase (iNOS/NOS2; #Mm00440502_m1) and the endogenous housekeeping
control genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH; #Mm99999915-g1) and
β actin (#Mm00607939-s1), which were purchased from Life Technologies (USA). The reac-
tions were performed and analyzed as previously described [52].
Statistical analysis
The data are expressed as arithmetic means ± standard deviation. Student t tests, ANOVA and
other appropriate tests were used to analyze the statistical significance of the observed differ-
ences. The Kaplan-Meier method was used to compare the survival times of the studied groups.
All statistical tests were performed using GraphPad Prism. Differences were considered statisti-
cally significant when P<0.05.
Supporting Information
S1 Fig. Immunization of C57BL/6 mice with rAdVax induced specific antibodies and T-cell
response. (A) Mice were s.c. primed-boosted with 2 × 108 plaque-forming units (PFU) of
rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2+rAdTS;
rAdVax) or the vehicle control saline at 6-week intervals. (B) Total (IgM+IgG) antibodies to
ASP2 and TS peptides were detected using ELISA. Each serum sample was serially diluted
(1:200, 1:400 and 1:800) before analysis. The data are presented as the means of three to five
mice serum samples per group. (C) Representative histogram of in vivo cytotoxicity assays of
normal splenocytes labeled with two concentrations of CFSE (CFSEHigh and CFSELow) that
were inoculated intravenously into the tail vein of immunized mice. CFSEHigh cells were pulsed
with the ASP2 peptide. CFSELow cells were unpulsed and served as internal controls. The
percentage of specific cell lysis was measured 20 hours later using FACS (R1-gated). Range of
percentages of specific lysis is shown for each experimental group. (D) Percentages of specific
lysis are shown for each experimental group. Data are expressed as the means ± SD of five mice
per group. (E) Numbers of CD8+IFNγ-secreting cells in the spleens of immunized mice were
determined by ELISpot using the H-2Kb-restricted VNHRFTLV peptide. Data are expressed as
the means ± SD of five mice per group. CCCP< 0.001, rAdVax-immunized compared with sa-
line-injected T. cruzi-infected mice. §§§P<0.001, rAdVax-immunized compared with rAdCtrl-
injected T. cruzi-infected mice.
(TIF)
S2 Fig. Heart parasitism and tissue injury are reduced in rAdVax-vaccinated mice chal-
lenged with the CL-Brener strain. (A) Mice were primed-boosted (s.c.) with 2 × 108 plaque-
forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each recombinant adenovirus vac-
cine construction (rAdASP2+rAdTS; rAdVax) or the vehicle control saline at 6-week intervals.
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Four weeks after the last immunization, the mice were challenged (i.p.) with 1000 blood trypo-
mastigotes (bt) of the CL-Brener T. cruzi Type VI strain and analyzed during the acute phase
of infection (23 dpi). (B) Quantitative immunohistochemical staining data for T. cruzi parasit-
ism (nests/100 microscopic fields) in the heart tissue. (C) Evaluation of CK-MB activity in the
serum of NI controls and T. cruzi-infected mice. The data are presented as the means ± SD of
seven to ten mice per group. P<0.001, experimental groups compared with NI controls.
CCP< 0.01 and CCCP< 0.001 rAdVax-immunized compared with saline-injected T. cruzi-
infected mice. §P< 0.05 and §§P< 0.01, rAdVax-immunized compared with rAdCtrl-injected
T. cruzi-infected mice.
(TIF)
S3 Fig. rAdVax reduced the number of CD8+ cells infiltrating the cardiac tissue in acutely
T. cruzi-infected mice.Quantification of inflammatory CD4+, CD8+ and F4/80+ (macrophage)
cells infiltrating the heart tissue of noninfected (NI) controls and mice injected with saline,
rAdCtrl or rAdVax challenged with the Colombian T. cruzi Type I strain and analyzed at
50 dpi. The data are presented as the means ± SD of seven to ten mice per group.  P<0.05,
 P<0.01 and P<0.001, experimental groups compared with NI controls. CCP<0.01,
rAdCtrl and rAdVax-immunized compared with saline-injected T. cruzi-infected mice.
§§P<0.01, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-infected mice.
(TIF)
S4 Fig. Cytokine expression in the serum of chronically T. cruzi-infected mice pre-therapy
and pos-therapy with rAdVax. Chronically Colombian-infected mice were evaluated for
cytokine expression in the serum at 120 dpi (pre-therapy) or primed-boosted with a mixture of
108 PFU of each adenovirus (rAdASP2+rAdTS) vaccine preparation and analyzed at 230 dpi
(pos-therapy). Representative dot plots showing the expression of (A) IL-17, IL-4, GM-CSF,
TNF and IFNγ or (B) IL-10, IL-6, IL-5, IL-2 and IL-1α.
(TIF)
S5 Fig. NOx levels in the serum are associated with cardiomyocyte lesion in chronic T. cruzi
infection. (A) Concentrations of NOx in the serum of noninfected (NI) controls and Colom-
bian-infected C57BL/6 mice. (B) No correlation was observed between parasitemia and CK-
MB activity levels during the chronic phase of infection. The results represent five to twelve
mice per experimental group.  P<0.05,  P<0.01 and P<0.001, experimental groups
compared with NI controls.
(TIF)
Acknowledgments
The authors would like to thank Mrs. Marcia Terra for technical assistance with the initial ade-
novirus production, Mr. Marcio Cipitelli and Ms. Nathália Vinagre for technical assistance
with the first IHS assay and Dr. Jaline Silverio for assistance with ECG recordings of the first
experiment, as well as the Program for Technological Development in Tools for Health
(PDTIS-Fiocruz) for the facilities on the Real Time PCR platform (RPT09A).
Author Contributions
Conceived and designed the experiments: IRP AVMOBRMMR RTG JLV. Performed the ex-
periments: IRP GVP VM AAdS BC OCM JLV. Analyzed the data: IRP GVP AAdS BC OCM
JLV. Wrote the paper: IRP AVMOBRMMR RTG JLV.
Therapeutic Vaccine for Chronic Chagas Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1004594 January 24, 2015 23 / 26
References
1. Rassi A Jr, Rassi A, Marin-Neto JA (2010). Chagas disease. Lancet. 375: 1388–1402. doi: 10.1016/
S0140-6736(10)60061-X PMID: 20399979
2. Lannes-Vieira J, de Araújo-Jorge TC, Soeiro Mde N, Gadelha P, Corrêa-Oliveira R (2010). The centen-
nial of the discovery of Chagas disease: facing the current challenges. PLoS Negl Trop Dis 4: e645.
doi: 10.1371/journal.pntd.0000645 PMID: 20614014
3. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, et al. (2010). The endless race between
Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med
12: e29. doi: 10.1017/S1462399410001560 PMID: 20840799
4. Tarleton RL (2007). Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 19: 430–
434. doi: 10.1016/j.coi.2007.06.003 PMID: 17651955
5. Silverio JC, Pereira IR, Cipitelli M da C, Vinagre NF, Rodrigues MM, et al. (2012). CD8+ T-cells ex-
pressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypano-
soma cruzi-elicited cardiomyopathy. PLoS Pathog 8: e1002645. doi: 10.1371/journal.ppat.1002645
PMID: 22532799
6. Parodi C, Padilla AM, Basombrío MA (2009). Protective immunity against Trypanosoma cruzi. Mem
Inst Oswaldo Cruz 1: 288–294. doi: 10.1590/S0074-02762009000900038 PMID: 19753487
7. Lee BY, Bacon KM, Wateska AR, Bottazzi ME, Dumonteil E, et al. (2012). Modeling the economic
value of a Chagas’ disease therapeutic vaccine. Hum Vaccin Immunother 8: 1293–1301. doi: 10.4161/
hv.20966 PMID: 22894964
8. Paiva CN, Castelo-Branco MT, Rocha JA, Lannes-Vieira J, Gattass CR (1999). Trypanosoma cruzi:
lack of T cell abnormalities in mice vaccinated with live trypomastigotes. Parasitol Res 85: 1012–1017.
doi: 10.1007/s004360050674 PMID: 10599925
9. Garg N, Tarleton RL (2002). Genetic immunization elicits antigen-specific protective immune re-
sponses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547–5555.
doi: 10.1128/IAI.70.10.5547-5555.2002 PMID: 12228281
10. Cazorla SI, Frank FM, Malchiodi EL (2009). Vaccination approaches against Trypanosoma cruzi infec-
tion. Expert Rev Vaccines 8: 921–935. doi: 10.1586/erv.09.45 PMID: 19538117
11. Nogueira RT, Nogueira AR, Pereira MC, Rodrigues MM, Galler R, et al. (2011). Biological and immuno-
logical characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi
Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome. Virol J 8: 127.
doi: 10.1186/1743-422X-8-127 PMID: 21418577
12. Gupta S, Garg NJ (2013). TcVac3 induced control of Trypanosoma cruzi infection and chronic myocar-
ditis in mice. PLoS One 8: 59434. doi: 10.1371/journal.pone.0059434 PMID: 23555672
13. Low HP, Santos MA, Wizel B, Tarleton RL (1998). Amastigote surface proteins of Trypanosoma cruzi
are targets for CD8+ CTL. J Immunol 160: 1817–1823. PMID: 9469442
14. Schenkman S, Eichinger D, Pereira ME, Nussenzweig V (1994). Structural and functional properties of
Trypanosoma trans-sialidase. Annu Rev Microbiol 48: 499–523. doi: 10.1146/annurev.mi.48.100194.
002435 PMID: 7826016
15. Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, et al. (2012). The revised Trypanosoma
cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect
Genet Evol 12: 240–253. doi: 10.1016/j.meegid.2011.12.009 PMID: 22226704
16. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, et al. (2006). Long-term protective
immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenovi-
ruses encoding amastigote surface protein-2 and trans-sialidase. HumGene Ther 17: 898–908. doi:
10.1089/hum.2006.17.898 PMID: 16972758
17. Haolla FA, Claser C, de Alencar BC, Tzelepis F, de Vasconcelos JR, et al. (2009). Strain-specific pro-
tective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine 27:
5644–5653. doi: 10.1016/j.vaccine.2009.07.013 PMID: 19635607
18. Pereira IR, Vilar-Pereira G, da Silva AA, Lannes-Vieira J (2014). Severity of chronic experimental Cha-
gas’ heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild
and severe disease. Mem Inst Oswaldo Cruz 109: 289–298. PMID: 24937048
19. Pereira IR, Vilar-Pereira G, da Silva AA, Moreira OC, Britto C, et al. (2014). Tumor necrosis factor is a
therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Cha-
gas’ heart disease. Mediators Inflamm 2014: 798078. doi: 10.1155/2014/798078 PMID: 25140115
20. Medeiros GA, Silvério JC, Marino AP, Roffê E, Vieira V, et al. (2009). Treatment of chronically Trypano-
soma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardi-
ac tissue damage. Microbes Infect 11: 264–273. doi: 10.1016/j.micinf.2008.11.012 PMID: 19100857
Therapeutic Vaccine for Chronic Chagas Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1004594 January 24, 2015 24 / 26
21. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. (2001). Bone marrow cells regenerate
infarcted myocardium. Nature 410: 701–705. doi: 10.1038/35070587 PMID: 11287958
22. Grisotto MG, D’Império Lima MR, Marinho CR, Tadokoro CE, Abrahamsohn IA, et al. (2001). Most par-
asite-specific CD8+ cells in Trypanosoma cruzi-infected chronic mice are down-regulated for T-cell re-
ceptor-alpha beta and CD8 molecules. Immunol 102: 209–217. doi: 10.1046/j.1365-2567.2001.01170.
x PMID: 11260326
23. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009). Relationship between CD107a expression
and cytotoxic activity. Cell Immunol 254: 149–154. doi: 10.1016/j.cellimm.2008.08.007 PMID:
18835598
24. Carvalho CM, Silverio JC, da Silva AA, Pereira IR, Coelho JM, et al. (2012). Inducible nitric oxide
synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: asso-
ciation with heart injury. PLoS Negl Trop Dis 6: e1644. doi: 10.1371/journal.pntd.0001644 PMID:
22590660
25. Rigato PO, de Alencar BC, de Vasconcelos JR, Dominguez MR, Araújo AF, et al. (2011). Heterologous
plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of pro-
tective long-lived CD8(+) T effector memory cells specific for a human parasite Trypanosoma cruzi. In-
fect Immun 79: 2120–2130. doi: 10.1128/IAI.01190-10 PMID: 21357719
26. Tzelepis F, de Alencar BC, Penido ML, Gazzinelli RT, Persechini PM, et al. (2006). Distinct kinetics of
effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinatedmice. Infect
Immun 74: 2477–2481. doi: 10.1128/IAI.74.4.2477-2481.2006 PMID: 16552083
27. de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, et al. (2009). Perforin and gamma
interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a
human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adeno-
virus 5 boost vaccination. Infect Immun 77: 4383–4395. doi: 10.1128/IAI.01459-08 PMID: 19651871
28. Barbosa RP, Filho BG, Dos Santos LI, Junior PA, Marques PE, et al. (2013). Vaccination using recom-
binants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on pro-
tection against Trypanosoma cruzi infection. PLoS One 8: e61795. doi: 10.1371/journal.pone.0061795
PMID: 23637908
29. Adams JE, Abendschein DR, Jaffe AS (1993). Biochemical markers of myocardial injury. Is MB creatine
kinase the choice for the 1990s? Circulation 88: 750–763. doi: 10.1161/01.CIR.88.2.750 PMID:
8339435
30. Higuchi ML, De Morais CF, Pereira Barreto AC, Lopes EA, Stolf N, et al. (1987). The role of active myo-
carditis in the development of heart failure in Chagas’ disease: a study based on endomyocardial biop-
sies. Clin Cardiol 10: 665–670. doi: 10.1002/clc.4960101113 PMID: 3677499
31. Strauss DG, Cardoso S, Lima JA, Rochitte CE, Wu KC (2011). ECG scar quantification correlates with
cardiac magnetic resonance scar size and prognostic factors in Chagas’ disease. Heart 97: 357–361.
doi: 10.1136/hrt.2010.210047 PMID: 21245474
32. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA (1991). Reversibility of cardiac fibrosis in
mice chronically infected with Trypanosoma cruzi under specific chemotherapy. Mem Inst Oswaldo
Cruz 86: 187–200. doi: 10.1590/S0074-02761991000200008 PMID: 1842413
33. Waghabi MC, Coutinho-Silva R, Feige JJ, Higuchi Mde L, Becker D, et al. (2009). Gap junction reduc-
tion in cardiomyocytes following transforming growth factor-beta treatment and Trypanosoma cruzi in-
fection. Mem Inst Oswaldo Cruz 104: 1083–1090. doi: 10.1590/S0074-02762009000800004 PMID:
20140368
34. Higuchi MD, Ries MM, Aiello VD, Benvenuti LA, Gutierrez PS, et al. (1997). Association of an increase
in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocar-
ditis. Am J Trop Med Hyg 56: 485–489. PMID: 9180594
35. Soares MB, Silva-Mota KN, Lima RS, Bellintani MC, Pontes-de-Carvalho L, et al. (2001). Modulation of
chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism.
Am J Pathol 159: 703–709. doi: 10.1016/S0002-9440(10)61741-5 PMID: 11485928
36. Pinto AM, Sales PC, Camargos ER, Silva AM. (2011). Tumour necrosis factor (TNF)-mediated NF-κB
activation facilitates cellular invasion of non-professional phagocytic epithelial cell lines by Trypano-
soma cruzi. Cell Microbiol 13: 1518–1529. doi: 10.1111/j.1462-5822.2011.01636.x PMID: 21749603
37. Tarleton RL, Zhang L, Downs MO (1997). “Autoimmune rejection” of neonatal heart transplants in ex-
perimental Chagas disease is a parasite-specific response to infected host tissue. Proc Natl Acad Sci U
S A 94: 3932–3937. doi: 10.1073/pnas.94.8.3932 PMID: 9108082
38. Rodrigues MM, Boscardin SB, Vasconcelos JR, Hiyane MI, Salay G, et al. (2003). Importance of CD8 T
cell-mediated immune response during intracellular parasitic infections and its implications for the de-
velopment of effective vaccines. An Acad Bras Cienc 75: 443–468. doi: 10.1590/S0001-
37652003000400005 PMID: 14605680
Therapeutic Vaccine for Chronic Chagas Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1004594 January 24, 2015 25 / 26
39. Miyahira Y (2008). Trypanosoma cruzi infection from the view of CD8+ T cell immunity–an infection
model for developing T cell vaccine. Parasitol Int 57: 38–48. doi: 10.1016/j.parint.2007.07.005 PMID:
17728174
40. Vasconcelos JR, Bruna-Romero O, Araujo AF, Dominguez MR, Ersching J, et al. (2012). Pathogen-
induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-
cell response: reversal by adenoviral vaccine. PLoS Pathog 8: e1002699. doi: 10.1371/journal.ppat.
1002699 PMID: 22615561
41. Lannes-Vieira J (2003). Trypanosoma cruzi-elicited CD8+ T cell-mediated myocarditis: chemokine re-
ceptors and adhesion molecules as potential therapeutic targets to control chronic inflammation? Mem
Inst Oswaldo Cruz 98: 299–304. doi: 10.1590/S0074-02762003000300002 PMID: 12886406
42. Lannes-Vieira J, Pereira IR, Vinagre NF, Arnez LE (2011). TNF-α and TNFR in Chagas disease: from
protective immunity to pathogenesis of chronic cardiomyopathy. Adv Exp Med Biol 691: 221–230.
PMID: 21153326
43. Pérez-Fuentes R, Guégan JF, Barnabé C, López-Colombo A, Salgado-Rosas H, et al. (2003). Severity
of chronic Chagas disease is associated with cytokine/antioxidant imbalance in chronically infected in-
dividuals. Int J Parasitol 33: 293–299. doi: 10.1016/S0020-7519(02)00283-7 PMID: 12670514
44. Silva JS, Machado FS, Martins GA (2003). The role of nitric oxide in the pathogenesis of Chagas dis-
ease. Front Biosci 8: 314–325. doi: 10.2741/1012 PMID: 12877141
45. Brunet LR (2001). Nitric oxide in parasitic infections. Int Immunopharmacol 1: 1457–1467. doi: 10.
1016/S1567-5769(01)00090-X PMID: 11515811
46. Quijano-Hernandez I, Dumonteil E (2011). Advances and challenges towards a vaccine against Cha-
gas disease. Hum Vaccin 7: 1184–1191. doi: 10.4161/hv.7.11.17016 PMID: 22048121
47. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, et al. (2013). Efficacy trial of a DNA/
rAd5 HIV-1 preventive vaccine. N Engl J Med 369: 2083–2092. doi: 10.1056/NEJMoa1310566 PMID:
24099601
48. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011). Adenovirus-5-vectored
P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective effica-
cy of the CSP component. PLoS One 6: e25868. doi: 10.1371/journal.pone.0025868 PMID: 22003411
49. Smaill F, JeyanathanM, Smieja M, Medina MF, Thanthrige-Don N, et al. (2013). A human type 5 ade-
novirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting
anti-adenovirus immunity. Sci Transl Med 5: 205ra134. doi: 10.1126/scitranslmed.3006843 PMID:
24089406
50. Nam JH (2009). Rapamycin: could it enhance vaccine efficacy? Expert Rev Vaccines 8: 1535–1539.
doi: 10.1586/erv.09.115 PMID: 19863245
51. Boscardin SB, Kinoshita SS, Fujimura AE, Rodrigues MM (2003). Immunization with cDNA expressed
by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infec-
tion. Infect Immun 71: 2744–2757. doi: 10.1128/IAI.71.5.2744-2757.2003 PMID: 12704149
52. Vilar-Pereira G, Silva AA, Pereira IR, Silva RR, Moreira OC, et al. (2012). Trypanosoma cruzi-induced
depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and
TNF-targeted therapeutic interventions. Brain Behav Immun 26: 1136–1149. doi: 10.1016/j.bbi.2012.
07.009 PMID: 22841695
Therapeutic Vaccine for Chronic Chagas Disease
PLOS Pathogens | DOI:10.1371/journal.ppat.1004594 January 24, 2015 26 / 26
